Key facts
- This page summarizes Vivek Garipalli's Form 4 filing for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV).
- 5 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 10 Jan 2025, 16:34.
Vivek Garipalli - 07 Jan 2025 Form 4 Insider Report for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- CLOV
- Reported as of
- 07 Jan 2025
- Net transaction value
- -$6,015,474
- SEC form
- 4
- Accepted by SEC
- 10 Jan 2025, 16:34:00 UTC
- Prior SEC filing
- 13 Aug 2024
- Next SEC filing
- 08 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/Peter J. Rivas as attorney-in-fact for Vivek Garipalli
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Vivek Garipalli filed Form 4 for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) on 10 Jan 2025.
Change
- Previous filing in this sequence was filed on 13 Aug 2024.
- Current net transaction value: -$6,015,474.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLOV
transaction
Class A Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +1,670,965
- Change %
- +119%
- Price
- $0.000000
- Shares after
- 3,080,232
- Date
- 07 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
CLOV
transaction
Class A Common Stock
Tax liability
- Transaction value
- $6,015,474
- Shares
- -1,670,965
- Change %
- -54%
- Price
- $3.60
- Shares after
- 1,409,267
- Date
- 07 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLOV
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- -3,342,698
- Change %
- -50%
- Price
- Shares after
- 3,342,699
- Date
- 07 Jan 2025
- Ownership
- Direct
- Underlying class
- Class B Common Stock
- Underlying amount
- 3,342,698
- Exercise price
- Footnotes
- F1, F3
CLOV
transaction
Derivative
Class B Common Stock
Options Exercise
- Transaction value
- Shares
- +3,342,698
- Change %
- +64%
- Price
- Shares after
- 8,575,308
- Date
- 07 Jan 2025
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 3,342,698
- Exercise price
- Footnotes
- F1, F2
CLOV
transaction
Derivative
Class B Common Stock
Options Exercise
- Transaction value
- Shares
- -1,670,965
- Change %
- -19%
- Price
- Shares after
- 6,904,343
- Date
- 07 Jan 2025
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 1,670,965
- Exercise price
- Footnotes
- F1, F2
CLOV
holding
Derivative
Class B Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 75,694,143
- Date
- 07 Jan 2025
- Ownership
- Held by NJ Healthcare Investment, LLC
- Underlying class
- Class A Common Stock
- Underlying amount
- 75,694,143
- Exercise price
- Footnotes
- F1, F4
CLOV
holding
Derivative
Class B Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 182,201
- Date
- 07 Jan 2025
- Ownership
- Held by Titus Ventures, LLC
- Underlying class
- Class A Common Stock
- Underlying amount
- 182,201
- Exercise price
- Footnotes
- F1, F4
CLOV
holding
Derivative
Class B Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,645,934
- Date
- 07 Jan 2025
- Ownership
- Held by Ceasar Ventures, LLC
- Underlying class
- Class A Common Stock
- Underlying amount
- 5,645,934
- Exercise price
- Footnotes
- F1, F4
CLOV
holding
Derivative
Class B Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,062,265
- Date
- 07 Jan 2025
- Ownership
- Held by Ceasar Clover, LLC
- Underlying class
- Class A Common Stock
- Underlying amount
- 2,062,265
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer.
Footnote F2
On January 7, 2025, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,671,733 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,670,695 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event.
Footnote F3
Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021.
Footnote F4
The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC, Titus Ventures, LLC, Caesar Ventures, LLC and Caesar Clover, LLC.